Physician profile
Angelo Mancuso
NPI 1992777627
$543.66
in general payments reported to CMS, 2019-2025
15 companies · $96.08 in 2025
The $96.08 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $40.94 · 2021: $42.56 · 2022: $52.45 · 2023: $56.62 · 2024: $82.23 · 2025: $96.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $118.04 | 2021-2024 | |
| Stemline Therapeutics INC. | $95.07 | 2019 | |
| Strata Skin Sciences, INC. | $64.70 | 2024-2025 | Xtrac |
| Biofrontera INC. | $38.20 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Novartis Pharmaceuticals Corporation | $33.92 | 2024-2025 | |
| Amgen INC. | $32.67 | 2020-2022 | |
| Dusa Pharmaceuticals, INC. | $24.86 | 2019 | |
| Incyte Corporation | $24.80 | 2025 | Opzelura |
| Merz North America, INC. | $24.48 | 2020 | |
| Pfizer INC. | $21.06 | 2022 | |
| Genentech USA, INC. | $19.42 | 2019 | |
| Boston Scientific Corporation | $13.39 | 2019 | |
| Janssen Biotech, INC. | $13.01 | 2023 | Tremfya |
| Celgene Corporation | $11.90 | 2019 | |
| Sensus Healthcare, INC. | $8.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angelo Mancuso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.